Ziprasidone: A review of its use in schizophrenia and schizoaffective disorder

Drugs

Volumn 62, Issue 8, 2002, Pages 1217-1251

  Gunasekara, Nishan S ^a   Spencer, Caroline M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

CP 88059; Pharmacodynamics; Pharmacokinetics; Schizophrenia; Therapeutic use; Ziprasidone

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CARBAMAZEPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HALOPERIDOL; HISTAMINE H1 RECEPTOR; KETOCONAZOLE; LITHIUM; OLANZAPINE; PROLACTIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2C RECEPTOR; ZIPRASIDONE;

AKATHISIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NEGATIVE SYNDROME; NEUROMODULATION; NONHUMAN; ORTHOSTATIC HYPOTENSION; QT INTERVAL; REVIEW; SCHIZOIDISM; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; VOMITING;

EID: 0036267331     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262080-00015     Document Type: Review

References (88)

1. Measuring the costs of schizophrenia: Implications for the post-institutional era in the US
2. Schizophrenia
3. Drug treatment of the negative symptoms of schizophrenia
4. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis
5. New drugs for the treatment of schizophrenic patients
6. New antipsychotics: A review of their current status and clinical potential
7. 2 receptors: An autoradiographic analysis in rat brain
8. 2 receptor blocking agent
9. i values
10. 2 affinities differentiate atypical and typical antipsychotic drugs
11. The mechanism of action of novel antipsyhotic drugs
12. 2 receptors
13. Pre-clinical pharmacology of new atypical antipsychotics in late stage development
14. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia
15. A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania
16. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study
17. Pharmacokinetics of ziprasidone in children and adolescents with Tourette's syndrome
18. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
19. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone
20. 11C-raclopride
21. 2 receptors by the neuroleptic ziprasidone(CP-88,059-01) determined by positron emission tomography
22. 2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone
23. Ziprasidone: Pharmacology, clinical progress and therapeutic promise
24. Pharmacodynamic differences between ziprasidone and haloperidol: Preliminary results of a 123I-IBZM SPECT study
25. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
26. The pharmacology of weight gain with antipsychotics
27. Effects of the novel antipsychotic ziprasidone on drug-disrupted prepulse inhibition in the rat
28. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
29. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers
30. Prolactin levels in patients taking risperidone and ziprasidone
31. Pharmacokinetics of intramuscular ziprasidone in healthy volunteers
32. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone
33. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans
34. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions
35. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function
36. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
37. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers
38. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers
39. Ziprasidone and the pharmacokinetics of a combined oral contraceptive
40. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid
41. The effects of ketoconazole on ziprasidone pharmacokinetics: A placebo-controlled crossover study in healthy volunteers
42. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers
43. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium
44. The population pharmacokinetics of intramuscular ziprasidone in healthy and schizophrenic subjects
45. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
46. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
47. An open-label, Japanese, phase II clinical trial of ziprasidone in the treatment of schizophrenia
48. Zipasidone versus olanzapine in schizophrenia: Results of a double-blind trial
49. Benefits of ziprasidone in stable outpatient schizphrenics switched from conventional antipsychotics, olanzapine, or risperidone
50. Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics
51. Replacement of depot antipsychotic therapy with oral ziprasidone
52. Haloperidol to ziprasidone switching strategies in schizophrenia
53. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia
54. Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia
55. Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data
56. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients
57. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind randomized trial
58. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis
59. A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol
60. Antipsychotic-induced weight gain: A comprehensive research synthesis
61. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death
62. Cardiovascular safety profile of ziprasidone: Clinical development data
63. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents
64. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex
65. The nature and prevalence of depression in chronic schizophrenic in-patients
66. Relapse in schizophrenia
67. Depression and social adjustment among chronic schizophrenia outpatients
68. Suicide among schizophrenics: A comparison of attempters and completed suicides
69. Depression in chronic schizophrenia
70. Depression, attempted suicide, and suicide in patients with chronic schizophrenia
71. Antipsychotic-associated weight gain and clinical outcome parameters
72. The current unsatisfactory state of relapse prevention in schizophrenic psychoses - Suggestions for improvement